Alexion

Alexion, founded in 1992, is a global biopharmaceutical leader specializing in the discovery, development, and commercialization of innovative therapies for severe and life-threatening rare disorders. The company maintains a robust pipeline focused on high-unmet-need conditions, leveraging advanced biotechnology to deliver life-changing treatments to patients worldwide. By prioritizing personalized medicine and patient support programs, Alexion has established itself as a pioneer in the orphan drug pharmaceutical sector.

Operating with a workforce of 5,000-10,000 employees, Alexion manages a complex global supply chain across 11 locations. The organization integrates clinical research, manufacturing, and commercial operations to ensure the secure delivery of therapeutic molecules. Meet Alexion's team to understand the organizational structure and leadership driving these specialized healthcare services. Their operational footprint supports a diverse portfolio of approved therapies, reinforcing their commitment to standard-setting medical innovation and patient-centric care.

With annual revenue reaching $1.7B, Alexion competes in a highly specialized market against major entities like Biogen, Regeneron, and BioMarin. The company’s strategic focus on rare disease therapeutics and its history of successful drug development programs position it as a significant player in the global healthcare landscape. Explore financial highlights to review detailed metrics, funding history, and market performance. Through continuous investment in R&D and strategic commercialization, Alexion remains dedicated to addressing complex medical challenges and improving patient outcomes across diverse therapeutic fields.